Skip to content

Impact of the 5A Nursing Model on Immune Balance and Lymph Node Metastasis in Primary Liver Cancer Patients Post-CyberKnife Treatment

Impact of the 5A Nursing Model on Immune Balance and Lymph Node Metastasis in Primary Liver Cancer Patients Post-CyberKnife Treatment

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500098852
Enrollment
Unknown
Registered
2025-03-14
Start date
2023-02-06
Completion date
Unknown
Last updated
2025-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver cancer

Interventions

5A nursing group :The implementation of the 5A care model, including Assess, Advise, Agree, Assist and Arrange, aims to improve the overall treatment response of patients through a systematic approach

Sponsors

First Hospital of Hebei Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patient age>=18 years and <=80 years; 2. Primary hepatocellular carcinoma (HCC) confirmed by pathology; 3. Child-Pugh grade A or B; 4. No important symptoms of portal hypertension; 5. ECOG physical performance status score 0-1; 6. Cyberknife treatment can be carried out safely; 7. The patient agrees to undergo follow-up examinations and sign the protocol informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients with a history of other malignant tumors in the past 5 years; 2. Patients with severe heart disease, unstable angina, recent myocardial infarction (within 6 months) or severe cardiac insufficiency; 3. Extensive extrahepatic metastasis; 4. Have recently undergone other liver surgery or treatment; 5. Female patients who are currently pregnant or breastfeeding; 6. Patients who do not agree to sign the informed consent of the protocol.

Design outcomes

Primary

MeasureTime frame
The density of CD8+ T cells and NK cells;The levels of IL-2 and TNF-a;lymph node metastasis incidence;

Countries

China

Contacts

Public ContactXin Su

First Hospital of Hebei Medical University

suxinss@126.com+86 189 3112 4853

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026